Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Eur Rev Med Pharmacol Sci ; 26(14): 5218-5224, 2022 07.
Article in English | MEDLINE | ID: mdl-35916820

ABSTRACT

OBJECTIVE: Implantation or replacement of a cardiovascular implantable electronic device (CIED) may be associated with complications, such as pocket hematomas and infections. This study aims to determine whether a lyophilized gentamycin-containing collagen implant (GCCI) reduces major CIED infections and pocket hematomas after implant. SUBJECTS AND METHODS: A retrospective study was conducted among patients who underwent implantation or replacement of CIED at the Tor Vergata Polyclinic (Rome, Italy) between June 2007 and November 2019. The primary combined endpoint was infection and hematoma occurrence through 12 months of follow-up post-procedure. The rate of single infectious complications, pocket hematomas or both were also assessed. RESULTS: We compared 475 patients treated with the GCCI (GCCI group) with 714 patients who did not receive it (control group). Complications occurred in 127 patients (11%); a statistically significant reduction of infections and pocket hematomas in the GCCI group was reported when compared with control patients (1% vs. 17%; p<0.0001). A total of 20 (2%) infectious events were reported, 102 (8%) patients developed a pocket hematoma, and 5 (0.4%) had both. The rate of single complications was significantly lower in GCCI group: infection 0.2% vs. 2.6% (p=0.002), pocket hematoma 0.6% vs. 13.8% (p<0.001). The association between antiplatelet/anticoagulation therapy and hematoma development was not statistically significant. CONCLUSIONS: The GCCI is a medical device that can be used in addition to local hemostasis and prophylactic doses of systemic antibiotics with the aim of reducing infective complications and pocket hematoma after permanent CIED implantation or replacement.


Subject(s)
Defibrillators, Implantable , Pacemaker, Artificial , Anticoagulants/therapeutic use , Collagen , Defibrillators, Implantable/adverse effects , Electronics , Gentamicins , Hematoma/etiology , Hematoma/prevention & control , Humans , Pacemaker, Artificial/adverse effects , Platelet Aggregation Inhibitors/therapeutic use , Retrospective Studies
2.
Br J Cancer ; 105(11): 1663-8, 2011 Nov 22.
Article in English | MEDLINE | ID: mdl-22068815

ABSTRACT

BACKGROUND: The aim of this study was to assess the value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in predicting late cardiotoxicity in patients treated with not-high-dose chemotherapy (NHDC), and to compare the predictive value of NT-proBNP and cardiac troponin I (cTnI). METHODS: In 71 patients undergoing NHDC with anthracyclines, NT-proBNP and cTnI levels were measured before and 24 h after each NHDC cycle. Left ventricular (LV) function was assessed by echocardiography at baseline, every two NHDC cycles, at the end of chemotherapy, and at 3-, 6- and 12-month follow-up. RESULTS: During NHDC, only NT-proBNP showed abnormal values. According to NT-proBNP behaviour, patients were divided into two groups: group A (n=50) with normal (n=23) or transiently elevated NT-proBNP levels (n=27), and group B (n=21) with persistently elevated NT-proBNP levels. At follow-up, LV impairment was significantly worse in group B than in group A. %Δ (baseline-peak) NT-proBNP was predictive of LV impairment at 3-, 6- and 12-month follow-up, with a cutoff of 36%. CONCLUSION: Serial measurements of NT-proBNP may be a useful tool for the early detection of patients treated with NHDC at high risk of developing cardiotoxicity.


Subject(s)
Anthracyclines/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Cardiovascular Diseases/blood , Cardiovascular Diseases/chemically induced , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Anthracyclines/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biomarkers, Tumor/blood , Breast Neoplasms/blood , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Docetaxel , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Echocardiography/methods , Epirubicin/administration & dosage , Epirubicin/adverse effects , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Follow-Up Studies , Humans , Middle Aged , Predictive Value of Tests , Taxoids/administration & dosage , Taxoids/adverse effects , Troponin I/blood , Ventricular Function, Left/drug effects
4.
Radiol Med ; 113(7): 1056-67, 2008 Oct.
Article in English, Italian | MEDLINE | ID: mdl-18797822

ABSTRACT

PURPOSE: Somatostatin receptor scintigraphy with [(111)In]-diethylene triamine pentaacetate acid (DTPA)-octreotide is an accurate method for detecting neuroendocrine tumours (NETs) but often does not provide clear anatomical localisation of lesions. The aim of this study was to assess the clinical usefulness of anatomical-functional image fusion. MATERIALS AND METHODS: Fifty-four patients with known or suspected NET were included in the study. Planar and single-photon-emission computed tomography (SPECT) imaging was performed using a dual-head gamma camera equipped with an integrated X-ray transmission system, and the images were first interpreted alone by two nuclear medicine physicians and then compared with SPECT/CT fusion images together with a radiologist. The improvement provided by SPECT/CT in the interpretation of SPECT data alone and any modification in patient management were recorded. RESULTS: Fusion images improved SPECT interpretation in 23 cases, providing precise anatomical localisation of increased tracer uptake in 20 cases and disease exclusion in sites of physiological uptake in 5. In 10 patients, SPECT/CT allowed definition of the functional significance of lesions detected by diagnostic CT. SPECT/CT data modified clinical management in 14 cases by changing the diagnostic approach in 8 and the therapeutic modality in 6. CONCLUSIONS: Our study demonstrates that image fusion is clearly superior to SPECT alone, allowing precise localisation of lesions and reducing false-positive results.


Subject(s)
Indium Radioisotopes , Neuroendocrine Tumors/diagnostic imaging , Octreotide/analogs & derivatives , Pentetic Acid/analogs & derivatives , Radiopharmaceuticals , Tomography, Emission-Computed, Single-Photon/methods , Tomography, X-Ray Computed/methods , Adult , Aged , Aged, 80 and over , False Positive Reactions , Female , Humans , Male , Middle Aged , Sensitivity and Specificity , Tomography, Emission-Computed, Single-Photon/instrumentation
SELECTION OF CITATIONS
SEARCH DETAIL
...